The interaction between amiodarone and the defibrillation threshold (DFT) is still controversial. We present a case with dilated cardiomyopathy and recurrent sustained monomorphic ventricular tachycardia who received an automatic implantable cardioverter defibrillator (AICD) while under long-term amiodarone treatment. AICD implantation was performed without thoracotomy. The transvenous lead was inserted via a left subclavian vein puncture and the patch was placed on the lateral chest wall, submuscularly. At the time of implantation a 35J shock was not successful in converting ventricular fibrillation to sinus rhythm, but a 40J rescue shock was successful. After discontinuation of amiodarone, DFT measurements were repeated. Sixteen days later DFT was still higher than 34J, but 71 days later it decreased to 20J. (Jpn Heart J 34: 221-226, 1993.) 
T HE issue of the defibrillation threshold (DFT) and amiodarone is still unresolved. Some studies have suggested that patients on long-term amiodarone treatment have significantly elevated DFTs.1)-4) Others have not found this increase in DFT or energy requirements for successful defibrillation.5), 6) In this report, we present a case with dilated cardiomyopathy and sustained monomorphic ventricular tachycardia (VT) who received an automatic implantable cardioverter defibrillator (AICD) while under long-term amiodarone treatment.
CASE RERORT
A 27-year-old male patient was referred to our clinic for treatment of and wall motions were diffusely hypokinetic. Cardiac catheterization and coronary angiography revealed generalized hypokinesia in the ventricles and normal coronary arteries. Ejection fraction was 32%. During VT intraarterial systolic blood pressure dropped from 103 to 78mmHg. All these findings were compatible with dilated cardiomyopathy.
We implanted an AICD with antitachycardia pacing capability (Ventak PRx 1705, CPI, St. Paul, MN, USA) under fentanyl anesthesia without thoracotomy using a transvenous lead (Endotak C0062, CPI) and submuscular patch (Endotak SQ 0063, CPI) as described elsewhere in the literature.7),8) Defibrillation threshold measurement was done using an external cardioverter defibrillator (Ventak ECD, model 2806, CPI). Ventricular fibrillation was induced with an external AC fibrillator. During implantation spontaneous clinical VT was converted to sinus rhythm with a 10J shock by the device. We could not find an acceptable DFT. Defibrillation threshold was less than 40J but it was above 35J. In spite of the high DFT we implanted the device because this patient had never experienced a ventricular fibrillation episode and his VT conversion threshold was at most 10J and probably less (we did not go down to lower values for measurement) and its rate was not high. Also, according to published reports amiodarone might be the cause of high DFT.
After implantation the device was programmed to monitor only mode for a week. We also stopped the amiodarone treatment 8 days after the implantation. During this period of time the patient was under continuous rhythm monitoring in the coronary care unit. Twenty-four days after implantation, an electrophysiologic study was performed using the device and an external stimulator. Induced clinical VT episodes were easily terminated by the device (burst pacing). Also, VT conversion to sinus rhythm was achieved with a 1J shock. Ventricular fibrillation induction for DFT measurement was difficult. DFT was between 34-40J. Two months after the implantation one spontaneous VT episode was converted by the antitachycardia pacing function of the device on the first attempt. The patient was not aware of this episode. The last DFT measurement was performed 71 days after cessation of amiodarone treatment. During this measurement, a bipolar catheter was inserted percutaneously and placed with its tip at the right ventricular apex, and ventricular fibrillation was induced with an AC fibrillator using this catheter. DFT was reduced to 20J. The measurement was 
